Biotech companies Biogen, Immunic Therapeutics, Kyverna Therapeutics, Progentos Therapeutics, TG Therapeutics and Zenas BioPharma are working on novel treatments for multiple sclerosis (MS). Each company is focused on various forms of the disease and aims to enhance therapeutic options, whether through inducing remyelination of axons, targeting B cells, providing neuroprotective benefits or through CAR-T therapies for autoimmune disorders. The global MS drug market is expected to grow to $38.94 billion by 2032.
Marimo RCE Vulnerability Exploited Within 10 Hours of Public Disclosure
A critical remote code execution (RCE) vulnerability in the open-source Python notebook platform Marimo was actively exploited less than 10 hours after its public disclosure.
